Innovative Inhaled Drug Delivery Developer Aerami Therapeutics to Merge with Special Purpose Acquisition Company FoxWayne Enterprises Acquisition Corp. to Become Public Company New entity poised to accelerate the development of Aerami’s diverse pipeline ofnext-generation inhaled therapies AER-901, Aerami’s proprietary inhaled, nebulized formulation of imatinib, targeted to...